Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition
Biomolecules · 19.11.2026 · 16 (11) · 1683
DOI: 10.3390/biom16111683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 19.11.2026. Verfasst von Alexis David und 6 weiteren Autor:innen. Die Arbeit nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Tours, Institut National de la Santé et de la Recherche Médicale, French Agence Nationale de la Recherche.
Abstract (Originalsprache)
Cathepsin S (CatS) is a protease that, unlike most human cysteine cathepsins, remains active at neutral pH, enabling functions in both the endolysosomal compartment and the extracellular space. It primes antigen presentation, remodels the extracellular matrix, and cleaves cytokines and receptors, placing it at the heart of inflammation, autoimmunity, pain, and cancer when its expression or activity is dysregulated. Despite the setbacks of CatK inhibitors, which warn against complete protease shutdown, the approval of brensocatib (a CatC/DPP1 inhibitor) for bronchiectasis supports the feasibility of therapeutic targeting of CatS. This review dissects how CatS is regulated, maps its substrates and roles in disease, and updates the landscape of natural and synthetic inhibitors that bind inside or outside the active site of the enzyme. Finally, it discusses emerging strategies for selective modulation of CatS activity.
Förderung
- University of Tours
- Institut National de la Santé et de la Recherche Médicale
- French Agence Nationale de la Recherche
Zitieren
APA
David, A., Brossier, C., Imbert, J., Saidi, A., Veillard, F., Lalmanach, G., & Lecaille, F. (2026). Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition. Biomolecules, 16(11), 1683. https://doi.org/10.3390/biom16111683
Vancouver
David A, Brossier C, Imbert J, Saidi A, Veillard F, Lalmanach G, et al. Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition. Biomolecules. 2026;16(11):1683. doi:10.3390/biom16111683
BibTeX
@article{David2026,
author = {David, Alexis and Brossier, Clarisse and Imbert, Jasmine and Saidi, Ahlame and Veillard, Florian and Lalmanach, Gilles and Lecaille, Fabien},
title = {Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {11},
pages = {1683},
doi = {10.3390/biom16111683}
}
EUVIMED